Nexstim NBS 5+ System Continues to Generate Interest in the US
Press release,Helsinki,6October2022 at12PM (EEST)
Nexstim NBS 5+ System Continues to Generate Interest in the US
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Drs. Lauren Marangell and Rayan Al Jurdi, experts in the treatment of major depression, have purchased a NBS 5+ system. Marangell and Al Jurdi, both previously faculty at Baylor College of Medicine, founded Brain Health Consultants and TMS Center as a private outpatient program offering state of the art treatment for people with depression and related disorders.
The NBS 5+ system, released in the United States in 2021, combines the capabilities of Nexstim’s NBS and NBT® systems. It thus enables the delivery of both diagnostic and therapeutic applications; diagnostic use meaning identifying the precise location and amount of stimulation required to active specific nerve cells for use across specialities such as neurosurgery, neuroradiology and psychiatry and therapeutic use referring to the treatment of major depressive disorder, for example.
Dr. LaurenMarangell noted: “We appreciate the technical sophistication of the Nexstim system and believe it will help us improve patient outcomes for the many people who have not responded to standard therapies.”
Mikko Karvinen, CEO of Nexstim, comments: “We are happy to welcome a new private clinic to our user community and appreciate their in-depth research and ultimate decision to choose Nexstim based on the level of sophistication we bring to the clinician treating patients with MDD. We are also pleased that the dual mode combined platform of the NBS5+ has been so well received as evidenced by that being the system of choice for sales in the United States this year.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.nexstim.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Anmodning om suspension i Investeringsforeningen Danske Invest og Investeringsforeningen Danske Invest Select28.11.2022 09:16:12 CET | pressemeddelelse
NASDAQ Copenhagen Nikolaj Plads 6 1007 København K 28. november 2022 Anmodning om suspension i Investeringsforeningen Danske Invest og Investeringsforeningen Danske Invest Select På grund af tekniske problemer anmodes om suspension på samtlige afdelinger under ovennævnte foreninger, indtil situationen er afklaret. Med venlig hilsen DANSKE INVEST MANAGEMENT A/S Tina Hjorth Hetting Head of Fund Products
Prepayments, Realkredit Danmark A/S28.11.2022 09:06:05 CET | Press release
To NASDAQ CopenhagenExecutive Board Lersø Parkallé 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 Telefax +45 4514 9622 28 November 2022 Company Announcement No 107/2022 Prepayments, Realkredit Danmark A/S Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes prepayments as at Friday 25 November 2022. Please find the data in the attached file. The information will also be available on www.rd.dk. Yours sincerely The Executive Board Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068. Attachments Nr. 107_Ekstraordinaere indfrielser pr 25.11.2022_ukBilag til selskabsmeddelelse nr. 107-2022
Ekstraordinære indfrielser, Realkredit Danmark A/S28.11.2022 09:06:05 CET | pressemeddelelse
Til NASDAQ KøbenhavnDirektionen Lersø Parkallé 100 2100 København Ø www.rd.dk Telefon 7012 5300 Telefax 4514 9622 28. november 2022 Selskabsmeddelelse nummer 107/2022 Ekstraordinære indfrielser, Realkredit Danmark A/S I medfør af lov om kapitalmarkeder §24 oplyses hermed om ekstraordinære indfrielser vedrørende Realkredit Danmark A/S pr. fredag den 25. november 2022. Oplysningerne fremgår af vedhæftede datafil. Oplysningerne vil endvidere kunne ses på Realkredit Danmarks hjemmeside på www.rd.dk. For yderligere informationer om dataformat og –indhold henvises til Nasdaq Copenhagen A/S’s hjemmeside. Med venlig hilsen Direktionen Eventuel henvendelse kan rettes til chefanalytiker Hella Gebhardt Rønnebæk, 45 13 20 68. Vedhæftede filer Nr. 107_Ekstraordinaere indfrielser pr 25.11.2022_dkBilag til selskabsmeddelelse nr. 107-2022
Municipality Finance issues RON 107.5 million notes under its MTN programme28.11.2022 09:00:00 CET | Press release
Municipality Finance Plc Stock exchange release 28 November 2022 at 10:00am (EET) Municipality Finance issues RON107.5million notes under its MTN programme Municipality Finance Plc issues RON 107.5 million notes on 29 November 2022. The maturity date of the notes is 29 November 2023. The notes bear interest at a fixed rate of 7.5% per annum. The notes are issued under MuniFin’s EUR 45 billion programme for the issuance of debt instruments. The offering circular, the supplemental offering circular and the final terms of the notes are available in English on the company's website at www.munifin.fi/investor-relations. MuniFin has applied for the notes to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 29 November 2022. Citigroup Global Markets Europe AG acts as the Dealer for the issue of the notes. MuniFin acquires funding in several different currencies. Most of the funding is acquired in euros and US dol
Transactions in connection with share buyback programme28.11.2022 08:30:00 CET | Press release
On 27 April 2022, Tryg A/S (“Tryg”) announced that a share buyback programme of DKK 5.0 billion had been initiated as a result of the sale of Codan Denmark. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 03 July 2023. Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis. The following transactions have been executed in the period 21 November 2022 to 25 November 2022: Number of sharesAvg. purchase price, DKKTransaction value, DKK21 November 2022 100,000 162.76 16,276,000 22 November 2022 110,000 163.94 18,033,400 23 November 2022 110,000 165.60 18,216,000 24 November 2022 90,000 165.36 14,882,400 25 November 2022 100,000 165.11 16,511,000 Accumulated for the period510,000-83,918